SEC Form 4 · accession 0001179110-17-014413
Editas Medicine, Inc. · EDIT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew A. F. Hack
Officer — Chief Financial Officer
Period of report
Nov 17, 2017
Accepted (ET)
Nov 21, 2017 · 4:04 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001650664
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 17, 2017 | M | 5,000 | $3.23 | A | 5,000 | D | |
| Common StockF2 | Nov 17, 2017 | S | 5,000 | $24.8146 | D | 0 | D | |
| Common Stock | Nov 20, 2017 | M | 5,000 | $3.23 | A | 5,000 | D | |
| Common StockF3 | Nov 20, 2017 | S | 5,000 | $25.3464 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F4 | $3.23 | Nov 17, 2017 | M | 5,000 | D | — | Jul 13, 2025 | Common Stock | 5,000 | 150,076 | D |
| Stock Option (right to buy)F4 | $3.23 | Nov 20, 2017 | M | 5,000 | D | — | Jul 13, 2025 | Common Stock | 5,000 | 145,076 | D |
Explanation of responses
- F1The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on September 15, 2017.
- F2This transaction was executed in multiple trades at prices ranging from $24.68 to $25.04. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3This transaction was executed in multiple trades at prices ranging from $25.04 to $25.78. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4This option was granted on July 14, 2015 and is scheduled to vest over four years with 25% of the shares having vested on July 1, 2016, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through July 1, 2019.